NextCell Pharma AB (FRA:65G) Change In Payables And Accrued Expense : €0.00 Mil (TTM As of Feb. 2025)

View and export this data going back to 2020. Start your Free Trial

What is NextCell Pharma AB Change In Payables And Accrued Expense?

NextCell Pharma AB's Change In Payables And Accrued Expense for the quarter that ended in Feb. 2025 was €0.00 Mil. It means NextCell Pharma AB's Accounts Payable & Accrued Expense stayed the same from Nov. 2024 to Feb. 2025 .

NextCell Pharma AB's Change In Payables And Accrued Expense for the fiscal year that ended in Aug. 2024 was €0.00 Mil. It means NextCell Pharma AB's Accounts Payable & Accrued Expense stayed the same from Aug. 2023 to Aug. 2024 .

NextCell Pharma AB Change In Payables And Accrued Expense Historical Data

The historical data trend for NextCell Pharma AB's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NextCell Pharma AB Change In Payables And Accrued Expense Chart

NextCell Pharma AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

NextCell Pharma AB Quarterly Data
	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

NextCell Pharma AB Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

NextCell Pharma AB Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of NextCell Pharma AB's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCell Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCell Pharma AB (FRA:65G) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

NXTCL:Sweden

Address

Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157

Website

http://www.nextcellpharma.com

NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.

NextCell Pharma AB Headlines

No Headlines